Idogen announces that the European Patent Office (EPO) has issued a Notice of Intention to Grant, which means that the patent office intends to grant Idogen’s patent application, covering the company’s tolerogenic vaccine technology.
A related patent application received a Notice of Allowance in Japan in December 2016. The patent, and its validation in key European countries, will provide Idogen’s tolerogenic vaccine technology with broad protection and further strengthens the company’s patent portfolio.
The European Patent Office has communicated its intention to grant Idogen’s Patent Application No. 11850142.8. The patent belongs to Idogen’s second patent family and covers Idogen’s technology for induction of IDO for treatment of autoimmune diseases and transplant rejection. A related application received “Notice of Allowance” in Japan in December 2016 and other applications are pending in Canada, the US and internationally. The granted patent will complement an earlier European Patent in Idogen’s first patent family, granted in December 2013. Final grant of this second patent by the EPO is expected to occur within two to three months following the completion of routine formalities by Idogen during the coming weeks.
”This patent provides very important protection for our tolerogenic vaccine platform on the European market – a key market for us. The decision that the European Patent Office intends to grant the patent is very pleasing,” commented CEO Lars Hedbys.